Our Vision

Precision Cancer Medicines for
Every Genetically-Defined Patient

Company Overview

Black Diamond Therapeutics: A Next-Wave Cancer Precision Medicine Company

Black Diamond Therapeutics has pioneered the development of selective medicines for patients with genetically-defined cancers driven by oncogenes activated by allosteric mutations.

The cornerstone of our approach derives from evolving trends in cancer clinical medicine. Genome-wide information – now routinely obtained from DNA testing of cancer patients – identifies clusters of uncharacterized genomic alterations. Today, new baskets of un-drugged oncogenic targets exist, leading to the identification of additional cancer patients in need of novel therapies.

Using our MAP platform, Black Diamond Therapeutics is pioneering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets, and to develop novel approaches to creating highly selective therapeutics.

Black Diamond's MAP Platform

Discover, Uncover and Target

Mutations

null

Black Diamond Therapeutics mines mutational hotspots for allosteric sites that produce potent oncogenes

Our computational platform integrates multiple forms of genome-level data with a deep understanding of mechanism, structure and dynamics.

Allostery

null

Black Diamond's platform provides insights into how allosteric mutations drive oncogenic activation

Allosterically activated oncogenes are identified by mapping mutation onto regulatory domains and regions involved protein-protein interfaces.

Protein Pharmacology

null

Black Diamond Therapeutics exploits this unique pharmacology to design drugs that are potent and selective for allosteric mutant oncogenes

Allosteric oncogenes are validated through screening in proprietary models of cancer.

The Science of Black Diamond

What is an allosteric mutation?

An allosteric mutation occurs distal to the site of action of an enzyme or receptor. In receptor tyrosine kinases, allosteric mutations occur distal to the the ATP binding site. 

Because large-scale conformational changes in proteins are a prerequisite for dimerization in oncogenic RTKs, allosteric mutations most frequently occur at, and structurally alter, the dimerization interface. 

How are allosteric mutations oncogenic?

Allosteric mutations activate tumor drivers and inactivate tumor suppressors through the large scale conformational change.

How are allosteric mutations oncogenic in RTK?

Allosteric mutations render RTK oncogenes ligand-independent.

Consequences of Allosteric Oncogenic Mutations In EGFR AND HER2

For the ErbB RTK oncogenes, EGFR and HER2, the selectivity of the ATP site is altered in comparison to the wild type receptors. Even though there is no change in the primary sequence of the ATP site, allosteric mutant ErbB RTKs exhibit unique drug selectivity.